Jaguar Health is supplementing its existing At-The-Market (ATM) offering program to allow for the sale of up to an additional $9.82 million in common stock. This move indicates the company's continued reliance on equity financing, which could lead to further share dilution for existing shareholders.
Jaguar Health is utilizing an ATM offering program to raise capital by selling up to $9.82 million worth of common stock. This is a continuation of their existing ATM program, which has been amended multiple times. The company is subject to limitations under General Instruction I.B.6 of Form S-3, which restricts the amount they can sell based on their public float. This filing updates the available amount they can sell under these restrictions. For traders, this signifies potential ongoing dilution, which could put downward pressure on the stock price in the short term as more shares enter the market. Long-term implications depend on how the raised capital is utilized to advance the company's operations and pipeline.